XTSXNGEN
Market cap141mUSD
Dec 23, Last price
2.90CAD
1D
-3.33%
1Q
13.73%
IPO
66.67%
Name
NervGen Pharma Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.86%
Rev. gr., 5y
%
Revenues
0k
Net income
-22m
L+23.61%
CFO
-11m
L-36.49%
Earnings
May 14, 2025
Profile
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 17,875 | 23,067 | 12,852 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (17,875) | (23,067) | (12,852) | ||||
NOPBT Margin | |||||||
Operating Taxes | (2,616) | (85) | |||||
Tax Rate | |||||||
NOPAT | (17,875) | (20,451) | (12,767) | ||||
Net income | (22,382) 23.61% | (18,106) 43.22% | (12,642) 13.11% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 867 | 19,763 | 18,902 | ||||
BB yield | -0.54% | -23.46% | -17.62% | ||||
| Debt | |||||||
Debt current | 92 | 86 | |||||
Long-term debt | 303 | 481 | |||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (11,265) | (21,885) | (16,929) | ||||
| Cash flow | |||||||
Cash from operating activities | (11,296) | (17,784) | (8,269) | ||||
CAPEX | (6) | (21) | (45) | ||||
Cash from investing activities | (139) | (21) | (45) | ||||
Cash from financing activities | 766 | 22,641 | 19,613 | ||||
FCF | (15,247) | (20,743) | (12,768) | ||||
| Balance | |||||||
Cash | 11,660 | 22,452 | 16,929 | ||||
Long term investments | |||||||
Excess cash | 11,660 | 22,452 | 16,929 | ||||
Stockholders' equity | (2,009) | 13,461 | 16,818 | ||||
Invested Capital | 197 | 283 | |||||
ROIC | |||||||
ROCE | 986.54% | ||||||
| EV | |||||||
Common stock shares outstanding | 59,290 | 52,649 | 39,289 | ||||
Price | 2.70 68.75% | 1.60 -41.39% | 2.73 22.42% | ||||
Market cap | 160,083 90.04% | 84,238 -21.46% | 107,260 49.78% | ||||
EV | 148,818 | 62,354 | 90,331 | ||||
EBITDA | (17,730) | (22,952) | (12,809) | ||||
EV/EBITDA | |||||||
Interest | 515 | ||||||
Interest/NOPBT | |||||||